Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Neurooncol. 2020 Mar 16;147(3):531–545. doi: 10.1007/s11060-020-03457-0

Figure 5.

Figure 5.

In vivo effect of AZD-1775 and Gemcitibine on orthotopic xenograft MYC-MB model in mice. A) D458 cells were injected in the mice cerebellum were allowed to form tumors. After establishment of tumors, the mice were randomized into four groups (n= 7); each group receiving Vehicle (containing DMSO) or AZD-1775(80mg/kg) or Gemcitabine (100 mg/kg) or combination of AZD-1775 and Gemcitabine. Kaplan-Meier survival plot showing no effect of AZD-1775 (80mg/kg) alone on survival but either Gemcitabine treatment (100mg/kg) alone or combination treatment with AZD-1775 improved animal significantly and to the same extent. B) At the end point, tumor tissues were collected from the mouse brain and analyzed for p-Cdc2 protein. PCdc2 decrease is seen only in the combination treatment.